Relation of impaired lymphocyte proliferative function to other major human immunodeficiency virus type 1-induced immunological changes.
Human immunodeficiency virus (HIV) type 1 (HIV-1) induces impairment of immune function reflected in reduced lymphocyte proliferative responses. Many other immune changes are induced by HIV-1, but their relationship to lymphocyte functional defects is not known. The present study was designed to correlate functional defects with other HIV disease parameters. Cryopreserved samples from 118 HIV-1-positive subjects and 40 seronegative individuals were examined. The main findings were that impaired proliferative responses to mitogens correlated with (i) decreased cell surface expression of the interleukin-2 receptor (CD25), (ii) increased expression of HLA-DR antigens on CD4 cells, (iii) reduced CD4 and increased CD8 cell numbers, and (iv) increased levels of serum immune complex dissociated p24 antigen. However, impaired function was not associated with increased serum neopterin, beta2-microglobulin, or soluble interleukin-2 receptor or with CD38 antigen expression on lymphocytes. In summary, proliferative functional impairment correlated with some, but not all, immunological changes associated with HIV-1 infection. Most of the phenotypic markers that correlated with altered function are cell surface molecules with significant roles in lymphocyte proliferation and were associated primarily with CD4 cells, compatible with the view that dysregulation of CD4 cells is responsible for impaired function.
Bass
H Z
HZ
Department of Microbiology and Immunology, UCLA School of Medicine, Los Angeles, California 90095, USA.
Fahey
J L
JL
Nishanian
P
P
Detels
R
R
Cumberland
W
W
Kemeny
M
M
Plaeger
S
S
D000936:Antigen-Antibody Complex / Q000276:immunology; D015703:Antigens, CD / Q000096:biosynthesis; D000944:Antigens, Differentiation, B-Lymphocyte / Q000096:biosynthesis; D015496:CD4-Positive T-Lymphocytes / Q000821:virology; D018414:CD8-Positive T-Lymphocytes / Q000378:metabolism / Q000821:virology; D015483:HIV Antibodies / Q000378:metabolism; D016655:HIV Core Protein p24 / Q000096:biosynthesis / Q000378:metabolism; D015658:HIV Infections / Q000276:immunology*; D015497:HIV-1 / Q000276:immunology*; D006684:HLA-DR Antigens / Q000096:biosynthesis; D006801:Humans; D007963:Leukocytes, Mononuclear / Q000187:drug effects / Q000276:immunology / Q000378:metabolism / Q000821:virology; D008213:Lymphocyte Activation; D008934:Mitogens / Q000494:pharmacology; D015375:Receptors, Interleukin-2 / Q000096:biosynthesis; D011990:Receptors, Transferrin
D000936:Antigen-Antibody Complex; D015703:Antigens, CD; D000944:Antigens, Differentiation, B-Lymphocyte; C068126:CD71 antigen; D015483:HIV Antibodies; D016655:HIV Core Protein p24; D006684:HLA-DR Antigens; D008934:Mitogens; D015375:Receptors, Interleukin-2; D011990:Receptors, Transferrin